Mechanisms of Therapeutic Resistance in Glioblastoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 7914
Special Issue Editors
Interests: neurosurgery; brain tumor; glioblastoma
Special Issue Information
Dear Colleagues,
Glioblastoma is an aggressive brain cancer with a dismal prognosis. Despite aggressive treatment including surgery followed by radiotherapy and adjuvant chemotherapy, the median survival remains less than two years. The causes of treatment failure are multifactorial and can be attributed to perturbations in tumor cells themselves or in the complex interactions between the tumor and the cells of the tumor microenvironment. Single-cell sequencing approaches in the past decade have revealed the transcriptomic and epigenetic changes driving tumor evolution during treatment, providing insights for treatment resistance. Immunotherapies have been successful in other solid malignancies but have had limited success in GBM due to several resistance mechanisms leading to a pro-tumoral microenvironment. Anti-angiogenic therapies show modest benefits but ultimately lead to treatment resistance through the adaptation of tumor cells. This Special Issue aims to address the advances in our understanding of how the biology of GBM tumor cells and the interactions between these tumors cells and the tumor microenvironment drive therapeutic resistance. We will also describe possible approaches to overcoming this resistance in order to improve patient outcomes.
In this Special Issue, original research articles and reviews are welcome. The research areas may include (but are not limited to) the following:
- The mechanisms of resistance to immune-cell-based therapies;
- The role of epigenetic alterations in glioblastoma stem cells in therapeutic resistance;
- Immunotherapeutic approaches targeting GBM stem cells;
- Strategies to overcome the blood–brain barrier in GBM treatment;
- The role of GBM stem cells in therapeutic resistance;
- Resistance to anti-angiogenic therapy in GBM;
- Using single-cell sequencing to define resistance mediators in GBM;
- Strategies to overcome the blood–brain barrier in GBM treatment;
- The mechanisms of radiation resistance in glioblastoma;
- The role of abnormal tumor metabolism in GBM therapeutic resistance;
- The role of oxidative stress in therapeutic resistance in GBM;
- The mathematical modeling of drug resistance in glioblastoma;
- The use of liquid biomarkers to monitor for GBM recurrence;
- The mechanisms of resistance to oncolytic viral therapies;
- The patterns of the epigenetic changes associated with GBM recurrence;
- The role of chromatin remodeling in therapeutic resistance;
- The role of the germline and somatic genomic landscape on therapeutic resistance in GBM;
- The role of GBM–neuron interactions in therapeutic resistance;
- The role of the innate immune response in resistance to GBM immunotherapy;
- DNA-damage-repair mechanisms in stem cells as a mechanism of radiation resistance in GBM;
- The mechanisms of the response to therapy-induced DNA alkylation damage in glioblastoma;
- Repurposing drugs to address therapeutic resistance in glioblastoma;
- Resistance to anti-angiogenic therapy in glioblastoma;
- Single-cell sequencing as a tool for defining the resistance mechanisms in glioblastoma.
We look forward to receiving your contributions.
Dr. Manish K. Aghi
Dr. Saket Jain
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- GBM microenvironment
- therapeutic resistance
- immunotherapy
- anti-angiogenic therapy
- tumor evolution
- single-cell genomics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.